{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:51:31Z","timestamp":1790484691332,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1136\/ijgc-2020-001658","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T17:05:57Z","timestamp":1603991157000},"page":"1935-1942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-0241","authenticated-orcid":false,"given":"Shih-Ern","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Tripcony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Sanday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis","family":"Perrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naven","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Land","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Obermair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Nascimento","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha","family":"Jagasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piksi","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Nicklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001658_bb0010","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1016\/S0020-7292(06)60033-7","article-title":"Carcinoma of the ovary","volume":"95","author":"Heintz","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1136\/ijgc-2020-001658_bb0015","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001658_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2020-001658_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"Onda","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001658_bb0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejca.2016.01.017","article-title":"Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): final analysis of peri-operative outcome","volume":"59","author":"Fagotti","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-001658_bb0035","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/ajo.12665","article-title":"The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: impact on clinical outcomes","volume":"57","author":"Nicklin","year":"2017","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"10.1136\/ijgc-2020-001658_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2016.05.022","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline","volume":"143","author":"Wright","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0045","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/IGC.0000000000001041","article-title":"European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery","volume":"27","author":"Querleu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001658_bb0050","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-001658_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007565.pub2","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2020-001658_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0065","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ygyno.2014.09.002","article-title":"Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer","volume":"135","author":"Colombo","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0075","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2019.30.e81","article-title":"Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?","volume":"30","author":"Yoneoka","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejogrb.2011.07.014","article-title":"Optimal timing of interval debulking surgery in advanced ovarian cancer: yet to be defined?","volume":"159","author":"Stoeckle","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2020-001658_bb0085","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.ejso.2018.01.097","article-title":"Complete cytoreduction after five or more cycles of neo-adjuvant chemotherapy confers a survival benefit in advanced ovarian cancer","volume":"44","author":"Phillips","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0090","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00280-004-0993-9","article-title":"Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis","volume":"56","author":"Dutta","year":"2005","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2020-001658_bb0095","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0100","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1097\/IGC.0000000000001108","article-title":"The impact of number of cycles of neoadjuvant chemotherapy on survival of patients undergoing interval debulking surgery for stage IIIC-IV unresectable ovarian cancer: results from a multi-institutional study","volume":"27","author":"Bogani","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001658_bb0105","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1245\/s10434-009-0558-6","article-title":"Does neoadjuvant chemotherapy increase optimal cytoreduction rate in advanced ovarian cancer? Meta-analysis of 21 studies","volume":"16","author":"Kang","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0110","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000449203","article-title":"Does the number of neoadjuvant chemotherapy cycles before interval debulking surgery influence survival in advanced ovarian cancer?","volume":"91","author":"Akladios","year":"2016","journal-title":"Oncology"},{"key":"10.1136\/ijgc-2020-001658_bb0115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00404-016-4256-x","article-title":"The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer","volume":"295","author":"Xu","year":"2017","journal-title":"Arch Gynecol Obstet"},{"key":"10.1136\/ijgc-2020-001658_bb0120","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ygyno.2019.02.019","article-title":"The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; a systematic review","volume":"153","author":"Timmermans","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001658_bb0125","author":"ClinicalTrials.gov","year":"2018","journal-title":"Neoadjuvant chemotherapy in epithelial ovarian cancer (GOGER-01)"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24012416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24012416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001658","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T01:25:10Z","timestamp":1753233910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24012416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S1048891X24012416"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001658","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}